George Hill - Ascletis Pharma Consultant Advisor
| ASCLF Stock | USD 0.18 0.00 0.00% |
Insider
George Hill is Consultant Advisor of Ascletis Pharma
| Age | 72 |
| Phone | 86 571 8538 9730 |
| Web | https://www.ascletis.com |
George Hill Latest Insider Activity
Tracking and analyzing the buying and selling activities of George Hill against Ascletis Pharma pink sheet is an integral part of due diligence when investing in Ascletis Pharma. George Hill insider activity provides valuable insight into whether Ascletis Pharma is net buyers or sellers over its current business cycle. Note, Ascletis Pharma insiders must abide by specific rules, including filing SEC forms every time they buy or sell Ascletis Pharma'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
George Hill over six months ago Disposition of 224 shares by George Hill of Five Below at 204.82 subject to Rule 16b-3 |
Ascletis Pharma Management Efficiency
The company has return on total asset (ROA) of (0.053) % which means that it has lost $0.053 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.0632) %, meaning that it generated substantial loss on money invested by shareholders. Ascletis Pharma's management efficiency ratios could be used to measure how well Ascletis Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Management Performance
| Return On Equity | -0.0632 | |||
| Return On Asset | -0.053 |
Ascletis Pharma Leadership Team
Elected by the shareholders, the Ascletis Pharma's board of directors comprises two types of representatives: Ascletis Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ascletis. The board's role is to monitor Ascletis Pharma's management team and ensure that shareholders' interests are well served. Ascletis Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ascletis Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jinzi Wu, Chairman Founder | ||
| Ming CPA, Company Sec | ||
| Yuemei Yan, Sr Operations | ||
| John MBA, Chief Officer | ||
| George Hill, Consultant Advisor | ||
| Hejingdao Wu, Sr Director | ||
| Handan He, Chief Officer | ||
| Kristjan Gudmundsson, Consultant Discovery |
Ascletis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Ascletis Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0632 | |||
| Return On Asset | -0.053 | |||
| Profit Margin | (2.24) % | |||
| Operating Margin | (3.11) % | |||
| Current Valuation | 116.15 M | |||
| Shares Outstanding | 1.09 B | |||
| Shares Owned By Insiders | 67.02 % | |||
| Shares Owned By Institutions | 1.94 % | |||
| Price To Book | 1.58 X | |||
| Price To Sales | 7.61 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Ascletis Pink Sheet
Ascletis Pharma financial ratios help investors to determine whether Ascletis Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ascletis with respect to the benefits of owning Ascletis Pharma security.